HS-130 is under clinical development by NightHawk Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HS-130’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HS-130 overview

HS-130 is under development for the treatment of non-small cell lung cancer (second line therapy) and multiple solid tumors (second line therapy). it is administered through intradermal route. It is a vaccine candidate derived from irradiated allogenic human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig.The therapeutic candidate is developed based on Combination pan-antigen cytotoxic therapy (ComPACT) technology.

NightHawk Biosciences overview

NightHawk Biosciences formerly Heat Biologics Inc, is a biopharmaceutical company which develops novel Immuno therapeutics and vaccines for the treatment of cancer. Its pipeline encompasses viagenpumatucel-L based investigational candidate targeted at the treatment of non-small cell lung cancer, and co-stimulatory antibodies targeted at tumors. The co-stimulatory antibodies harness human body’s natural antigen specific immune response to reprogram the immune system to offer durable clinical outcomes. NightHawk Biosciences’ off-the-shelf therapies are based on its proprietary T-cell activating platform (TCAP), which turns immunologically cold tumors hot. It operates through its subsidiaries in the US, Germany and Australia. NightHawk Biosciences is headquartered in Durham, North Carolina, the US.

For a complete picture of HS-130’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.